Changes of cytokines in patients with Graves' ophthalmopathy before and after treatment with glucocorticoid

doi:10.3969/j.issn.1006-7795.2024.03.005

Abstract

Abstract: Objective To explore the correlation between the changes of serum cytokine in active Graves' ophthalmopathy (GO) patients before and after glucocorticoid therapy and efficacy of glucocorticoid therapy.Methods Twenty-eight patients diagnosed with GO in the Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University from January 2021 to January 2024 were selected. All patients were diagnosis as active GO patients (CAS≥3). Patients received regular weekly glucocorticoid weekly pulse therapy with a total dose of 4.5 g. The concentrations of 34 cytokines in serum were examined. Meanwhile, clinical indicators such as gender, age, liver and kidney function, thyroid function before and after treatment, and antibodies of all subjects were collected. Results The levels of interleukins (IL)（IL-1α, IL-1β, IL-1Rα, IL-2Rα, IL-6, IL-8, IL-18, IL-12p40 and IL-16）and cytokines including cutaneous T cell attraction chemokines（CTACK), monocyte chemoattractant protein-1（MCP-1）, macrophage migration inhibitory factor (MIF), stromal cell-derived factor 1α (SDF-1α), basic fibroblast growth factor（basic-FGF）, granulocyte colony-stimulating Factor (G-CSF), tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) in active GO patients after glucocorticoid treatment were significantly decreased compared with before treatment (P<0.05). Conclusion The levels of interleukins（IL-1α, IL-1β, IL-1Rα, IL-2Rα, IL-6, IL-8, IL-18, IL-12p40 and IL-16）and cytokines including CTACK, MCP-1, MIF, SDF-1α, basic-FGF、G-CSF, TNF-α and IFN-γ in active GO patients decreased significantly after glucocorticoid therapy, suggesting that these cytokines may be involved in the efficacy of glucocorticoid therapy for GO.

Key words: Graves' ophthalmopathy, active phase, glucocorticoid, cytokines, interleukin

CLC Number:

Shi Tingting, Xie Rongrong, Xin Zhong, Liu Wei, Su Zhiyan, Yang Jinkui. Changes of cytokines in patients with Graves' ophthalmopathy before and after treatment with glucocorticoid[J]. Journal of Capital Medical University, 2024, 45(3): 399-405.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2024.03.005

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2024/V45/I3/399

References

［1］Subekti I, Soewondo P, Soebardi S, et al. Practical guidelines management of Graves ophthalmopathy［J］. Acta Med Indones, 2019, 51(4): 364－371.
［2］Antonelli A, Fallahi P, Elia G, et al. Graves' disease: clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy［J］. Best Pract Res Clin Endocrinol Metab, 2020, 34(1): 101388.
［3］Bartalena L, Tanda M L. Current concepts regarding Graves' orbitopathy［J］. J Intern Med, 2022, 292(5): 692－716.
［4］Bartalena L, Kahaly G J, Baldeschi L, et al. The 2021 European Group on Graves' Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy［J］. Eur J Endocrinol, 2021, 185(4): G43-G67.
［5］Moleti M, Giuffrida G, Sturniolo G, et al. Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy［J］. Endocrine, 2016, 54(1): 259－268.
［6］Fallahi P, Ferrari S M, Elia G, et al. Cytokines as targets of novel therapies for graves' ophthalmopathy［J］. Front Endocrinol (Lausanne), 2021, 12: 654473.
［7］Zhang P, Zhu H. Cytokines in thyroid-associated ophthalmopathy［J］. J Immunol Res, 2022, 2022: 2528046.
［8］Longo C M, Higgins P J. Molecular biomarkers of Graves' ophthalmopathy［J］. Exp Mol Pathol, 2019, 106: 1－6.
［9］Gonnella D. The Th1 chemokine MIG in Graves' ophthalmopathy［J］. Clin Ter, 2019, 170(5): e368-e372.
［10］谢荣荣, 史婷婷, 信中, 等. Graves眼病患者血浆细胞因子浓度与临床活动度的相关性分析［J］. 首都医科大学学报, 2023, 44(3): 407－412.
［11］Macovei M L, Azis ü, Gheorghe A G, et al. A systematic review of euthyroid Graves' disease (review)［J］. Exp Ther Med, 2021, 22(5): 1346.
［12］Bahn R S. Current insights into the pathogenesis of Graves' ophthalmopathy［J］. Horm Metab Res, 2015, 47(10): 773－778.
［13］Ferrari S M, Paparo S R, Ragusa F, et al. Chemokines in thyroid autoimmunity［J］. Best Pract Res Clin Endocrinol Metab, 2023, 37(2): 101773.
［14］Fang S, Lu Y, Huang Y, et al. Mechanisms that underly t cell immunity in Graves' orbitopathy［J］. Front Endocrinol (Lausanne), 2021, 12: 648732.
［15］Elia G, Fallahi P, Ragusa F, et al. Precision medicine in Graves' disease and ophthalmopathy［J］. Front Pharmacol, 2021, 12: 754386.
［16］Kumar S, Bahn R S. Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with graves' ophthalmopathy［J］. J Clin Endocrinol Metab, 2003, 88(9): 4246－4250.
［17］Kishazi E, Dor M, Eperon S, et al. Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy［J］. Sci Rep, 2018, 8(1): 10792.
［18］Song R H, Wang B, Yao Q M, et al. Proteomics screening of differentially expressed cytokines in tears of patients with Graves' ophthalmopathy［J］. Endocr Metab Immune Disord Drug Targets, 2020, 20(1): 87－95.
［19］Li H Y, Ma C, Liu W, et al. Gypenosides protect orbital fibroblasts in graves ophthalmopathy via anti-inflammation and anti-fibrosis effects［J］. Invest Ophthalmol Vis Sci, 2020, 61(5): 64.
［20］Du J, Wang X, Tan G, et al. Predisposition to Graves' disease and Graves' ophthalmopathy by genetic variants of IL2RA［J］. J Mol Med, 2021, 99(10): 1487－1495.
［21］Virakul S, Heutz J W, Dalm V A S H, et al. Basic FGF and PDGF-BB synergistically stimulate hyaluronan and IL-6 production by orbital fibroblasts［J］. Mol Cell Endocrinol, 2016, 433: 94－104.
［22］Liu Y H, Shen C Y, Tsai F J. Association of variant on the promoter of cluster of differentiation 74 in graves disease and graves ophthalmopathy［J］. Biosci Rep, 2020, 40(8): BSR20202072.
［23］Fernando R, Atkins S J, Smith T J. Intersection of chemokine and TSH receptor pathways in human fibrocytes: emergence of CXCL-12/CXCR4 cross talk potentially relevant to thyroid-associated ophthalmopathy［J］. Endocrinology, 2016, 157(10): 3779－3787.

[1]	Li Yujia, Guan Dexiu, Guo Shu, Guo Jing, Xu Xiwei. Clinical features and genetic analysis of very early-onset inflammatory bowel disease caused by interleukin-10 receptor A gene mutation [J]. Journal of Capital Medical University, 2024, 45(1): 140-148.
[2]	Xie Rongrong, Shi Tingting, Xin Zhong, Cao Xi, Yang Jinkui. Analysis of the correlation between levels of cytokines and the clinical active severity in patients with Graves ophthalmopathy [J]. Journal of Capital Medical University, 2023, 44(3): 407-412.
[3]	Peng Dan, Pang Jie, Shi Yifan, Cui Lele, Xu Yingjie, Li Yan, Cui Ye, Chen Yan, Yuan Huihui, Qin Xiaofeng, Lyu Zhe, Wang Wei, Sun Ying. Streptococcus pneumoniae infection at early stage of life affect the severity of asthma induced by exposure to the same bacterial antigens in adulthood [J]. Journal of Capital Medical University, 2023, 44(2): 212-220.
[4]	Hu Shuyuan, Zhang Kaiyuan, Gu Yaqin, Li Jingka, Zhou Chen, Ji Xunming, Duan Jiangang. Exploration of glucocorticoid combined with anticoagulation in acute/subacute severe cerebral venous thrombosis [J]. Journal of Capital Medical University, 2023, 44(2): 280-288.